Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Genetron Holdings, a China-based precision cancer treatment developer backed by gene engineering services provider Vcanbio Cell & Gene Engineering, has raised $256m in an initial public offering on the Nasdaq Global Market. The offering consisted of 16 million American Depositary Shares (ADSs) – each representing five ordinary shares – priced at $16.00 each. The company…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.